Search for other papers by Charlotte Höybye in
Google Scholar
PubMed
Search for other papers by Beverly M K Biller in
Google Scholar
PubMed
Search for other papers by Jean-Marc Ferran in
Google Scholar
PubMed
Search for other papers by Murray B Gordon in
Google Scholar
PubMed
Search for other papers by Nicky Kelepouris in
Google Scholar
PubMed
Search for other papers by Navid Nedjatian in
Google Scholar
PubMed
Search for other papers by Anne H Olsen in
Google Scholar
PubMed
Search for other papers by Matthias M Weber in
Google Scholar
PubMed
for AGHD (GH treated) who were enrolled in two non-interventional, multicentre studies: the NordiNet ® International Outcome Study (IOS) and the American Norditropin ® Studies: Web-Enabled Research (ANSWER) Program ( 16 , 17 ). The CV risks of
Search for other papers by Alicia Romano in
Google Scholar
PubMed
Search for other papers by Juan Pablo Kaski in
Google Scholar
PubMed
Search for other papers by Jovanna Dahlgren in
Google Scholar
PubMed
Search for other papers by Nicky Kelepouris in
Google Scholar
PubMed
Search for other papers by Alberto Pietropoli in
Google Scholar
PubMed
Search for other papers by Tilman R Rohrer in
Google Scholar
PubMed
Search for other papers by Michel Polak in
Google Scholar
PubMed
observational studies. Materials and methods Study design and ethics The NordiNet® International Outcomes Study (IOS; NCT00960128) and ANSWER Program (NCT01009905) were observational, multicentre studies monitoring the real-world long-term outcomes
Search for other papers by Alexander A L Jorge in
Google Scholar
PubMed
Search for other papers by Thomas Edouard in
Google Scholar
PubMed
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genova, Italy
Search for other papers by Mohamad Maghnie in
Google Scholar
PubMed
Search for other papers by Alberto Pietropoli in
Google Scholar
PubMed
Search for other papers by Nicky Kelepouris in
Google Scholar
PubMed
Search for other papers by Alicia Romano in
Google Scholar
PubMed
Search for other papers by Martin Zenker in
Google Scholar
PubMed
Search for other papers by Reiko Horikawa in
Google Scholar
PubMed
( 21 , 22 , 23 ). The current analysis used data from a subset of NS patients enrolled in the ANSWER program® and GHLIQUID-4020, including only patients with confirmed PTPN11 mutation status. Data from the Nordinet® International Outcome Study (IOS
Search for other papers by Anita Hokken-Koelega in
Google Scholar
PubMed
Search for other papers by Aart-Jan van der Lely in
Google Scholar
PubMed
Search for other papers by Berthold Hauffa in
Google Scholar
PubMed
Search for other papers by Gabriele Häusler in
Google Scholar
PubMed
Search for other papers by Gudmundur Johannsson in
Google Scholar
PubMed
Search for other papers by Mohamad Maghnie in
Google Scholar
PubMed
Search for other papers by Jesús Argente in
Google Scholar
PubMed
Search for other papers by Jean DeSchepper in
Google Scholar
PubMed
Search for other papers by Helena Gleeson in
Google Scholar
PubMed
Search for other papers by John W Gregory in
Google Scholar
PubMed
Search for other papers by Charlotte Höybye in
Google Scholar
PubMed
Search for other papers by Fahrettin Keleştimur in
Google Scholar
PubMed
Search for other papers by Anton Luger in
Google Scholar
PubMed
Search for other papers by Hermann L Müller in
Google Scholar
PubMed
Search for other papers by Sebastian Neggers in
Google Scholar
PubMed
Search for other papers by Vera Popovic-Brkic in
Google Scholar
PubMed
Search for other papers by Eleonora Porcu in
Google Scholar
PubMed
Search for other papers by Lars Sävendahl in
Google Scholar
PubMed
Search for other papers by Stephen Shalet in
Google Scholar
PubMed
Search for other papers by Bessie Spiliotis in
Google Scholar
PubMed
Search for other papers by Maithé Tauber in
Google Scholar
PubMed
independent research grants for multicentre studies from Pfizer, Novo Nordisk, Ipsen and Lilly; received lecture fees from Pfizer and Novo Nordisk; and received fee for KIGS Steering Committee participation. Charlotte Höybye: member of Nordinet IOS, Patro and
Search for other papers by Robert Rapaport in
Google Scholar
PubMed
Search for other papers by Peter A Lee in
Google Scholar
PubMed
Nemours/DuPont Hospital for Children, Wilmington, Delaware, USA
Search for other papers by Judith L Ross in
Google Scholar
PubMed
Search for other papers by Paul Saenger in
Google Scholar
PubMed
Search for other papers by Vlady Ostrow in
Google Scholar
PubMed
Search for other papers by Giuseppe Piccoli in
Google Scholar
PubMed
: longitudinal analysis of growth-hormone-naive patients enrolled in the NordiNet(R) International Outcome Study and the ANSWER Program . International Journal of Pediatric Endocrinology 2015 2015 17 . ( https://doi.org/10.1186/s13633-015-0015-1 ) 26351466
Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden
Search for other papers by Charlotte Höybye in
Google Scholar
PubMed
Search for other papers by Laia Faseh in
Google Scholar
PubMed
Department of Medicine, Karlstad Hospital, Karlstad, Sweden
Search for other papers by Christos Himonakos in
Google Scholar
PubMed
Search for other papers by Tomasz Pielak in
Google Scholar
PubMed
Search for other papers by Jesper Eugen-Olsen in
Google Scholar
PubMed
was stored in a bio-bank (at −70°C). The patients were enrolled in two post-marketing observational databases of GH treatment in adults with GHD, NordiNet (NovoNordisk) and KIMS (Pfizer). Data on demography (age at baseline, gender, smoking), weight
EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France
Search for other papers by Nathalie Ly in
Google Scholar
PubMed
EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France
Search for other papers by Sophie Dubreuil in
Google Scholar
PubMed
EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France
Sorbonne University, Paris, France
Search for other papers by Philippe Touraine in
Google Scholar
PubMed
Höybye C Carroll P Gordon MB Birkegård AC Kelepouris N Nedjatian N Weber MM . Pregnancy outcomes in women receiving growth hormone replacement therapy enrolled in the NordiNet® International Outcome Study (IOS) and the American Norditropin
Search for other papers by Régis Coutant in
Google Scholar
PubMed
Pediatric team of the Clinical Investigation Center 9302/INSERM, Hospital of Children, Toulouse, France
Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051 - Université Toulouse III, Toulouse, France
Search for other papers by Maithé Tauber in
Google Scholar
PubMed
Search for other papers by Béatrice Demaret in
Google Scholar
PubMed
Search for other papers by Robin Henocque in
Google Scholar
PubMed
Search for other papers by Yves Brault in
Google Scholar
PubMed
Search for other papers by François Montestruc in
Google Scholar
PubMed
Patient-Reported Outcomes Unit (PROQOL), UMR 1123, University Paris Cité, INSERM, Paris, France
Search for other papers by Olivier Chassany in
Google Scholar
PubMed
Search for other papers by Michel Polak in
Google Scholar
PubMed
Search for other papers by the QOLITHOR Study Group in
Google Scholar
PubMed
: NordiNet IOS and ANSWER . Journal of Clinical Endocrinology and Metabolism 2021 106 1728 – 1741 . ( https://doi.org/10.1210/clinem/dgab080 ) 9 Fisher BG & Acerini CL . Understanding the growth hormone therapy adherence paradigm: a systematic
Search for other papers by Robert Rapaport in
Google Scholar
PubMed
Search for other papers by Jan M Wit in
Google Scholar
PubMed
Search for other papers by Martin O Savage in
Google Scholar
PubMed
Miller BS Rohrer TR Pietropoli A Ostrow V Ross J Treatment of children with GH in the United States and Europe: long-term follow-up from NordiNet® IOS and ANSWER Program . Journal of Clinical Endocrinology and Metabolism 2019 104 4730